Candel Therapeutics, Inc.

Rentabilité sur six mois: -40.76%
Rendement en dividendes: 0%
Secteur: Healthcare

5.13 $

0 $ 0%
3.8 $
12.21 $

paper.min_max_per_year

Calendrier des promotions Candel Therapeutics, Inc.

À propos de l'entreprise Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

Paramètres de base

IPO date
2021-07-27
ISIN
US1374041093
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 1064.07 1
P/BV 4.15 4
P/E 0 0
Efficacité
Nom Signification Grade
ROA -74.53 0
ROE -139.56 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.2586 10
Debt/Ratio 0.1261 10
Debt/Equity 0.6112 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -75.2 0
Rentabilité Ebitda, % 512.91 10
Rentabilité EPS, % 47.01 6

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 5.13 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 5.46 $ 0 $ 0 $ -6.04 % 0 % 0 %
common.calendar.number_days.30d 5.43 $ 5.13 $ 6.04 $ -5.52 % 0 % 0 %
common.calendar.number_days.90d 4.97 $ 4.39 $ 6.04 $ 3.22 % 0 % 0 %
common.calendar.number_days.180d 8.66 $ 4.39 $ 12.21 $ -40.76 % 0 % 0 %
common.calendar.number_days.1y 6.27 $ 3.8 $ 12.21 $ -18.18 % 0 % 0 %
common.calendar.number_days.3y 3.4 $ 0.675 $ 14 $ 50.88 % 0 % 0 %
common.calendar.number_days.5y 0.675 $ 0.675 $ 14 $ 760 % 0 % 0 %
common.calendar.number_days.10y 0.675 $ 0.675 $ 14 $ 760 % 0 % 0 %
common.calendar.number_days.ytd 7.81 $ 4.39 $ 12.21 $ -34.31 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Seshu Tyagarajan Ph.D. Chief Technical & Development Officer 335.27k 1968 (57 années)
Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer 506.76k 1978 (47 années)
Ms. Ileen B. Winick Chief People Officer N/A
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer N/A 1961 (64 année)
Dr. William Garrett Nichols M.D., M.S. Chief Medical Officer N/A 1969 (56 années)
Mr. Charles Schoch Interim CFO, Principal Accounting Officer, Treasurer & Secretary N/A 1985 (40 années)
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. President, CEO & Director 1961 (64 année)

Informations sur l'entreprise

Adresse: United States, Needham. MA, 117 Kendrick Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.candeltx.com